PHARMACOTHERAPY PRINCIPLES & PRACTICE
4th Edition — Chisholm-Burns and colleagues
Enhanced Original Exam Study Guide
Disease-state pharmacotherapy • drug selection • dosing • monitoring • safety • patient care
Created from the public Stuvia preview and the publicly available 4th-edition chapter architecture. This guide is original and does not
reproduce the 344-page paid test bank.
Exam focus: pharmacology foundations • medication safety • geriatrics • pediatrics • palliative care • cardiovascular • respiratory • GI
• renal/electrolytes • neurologic • psychiatric • infectious disease • endocrine • hematology • oncology • rheumatology • dermatology •
women's/men's health • patient monitoring
Pharmacotherapy Principles & Practice 4th Ed — Original Enhanced Study Guide Page 1
, 1. SOURCE REVIEW & STUDY STRATEGY
The linked Stuvia listing is a 344-page Q&A;/test-bank document written for academic year 2021/2022, uploaded January 7, 2022
and updated January 13, 2022. Its public preview starts with Chapter 1 and questions on generic/official drug names,
drug-information resources, FDA approval, controlled-substance scheduling, OTC drugs, injectable references, and
medication-history reconciliation. ■cite■turn0view0■
The official McGraw Hill listing identifies the 4th edition as a 2015 publication (copyright 2016) by Marie A. Chisholm-Burns, Terry L.
Schwinghammer, Barbara G. Wells, Patrick M. Malone, Joseph T. DiPiro and Jill M. Kolesar. The text uses disease-based chapters
with clinical presentation/diagnosis, patient encounters, therapeutic recommendations, dosing and monitoring.
■cite■turn0search0■turn0search7■
Publicly available contents show four introductory chapters followed by 98 disease-based chapters. The organ-system sections
include cardiovascular, respiratory, gastrointestinal, renal, neurologic, psychiatric, infectious disease, endocrine,
hematologic/oncologic, rheumatologic, dermatologic and other common clinical areas. ■cite■turn0search1■turn0search5■
How to study a pharmacotherapy chapter
• 1) Identify the disease and therapeutic goals.
• 2) Confirm diagnosis and severity.
• 3) Identify patient-specific factors: age, pregnancy, renal/hepatic function, allergies, comorbidities and prior treatment.
• 4) Choose nonpharmacologic and pharmacologic therapy.
• 5) Select the agent using efficacy, safety, contraindications, interactions, adherence and cost/access.
• 6) Define starting dose, titration and duration.
• 7) Establish monitoring and measurable treatment targets.
• 8) Reassess response and adverse effects; de-escalate or intensify when indicated.
2. FOUNDATIONS OF PHARMACOTHERAPY
Drug names
Name Meaning
Chemical Describes molecular structure; usually least useful for routine patient communication.
Generic/nonproprietary Standardized name used across manufacturers.
Brand/proprietary Manufacturer-associated trade name.
Official Name recognized in an official compendium/regulatory context; terminology can differ from generic usage.
Drug information hierarchy
• Use the most authoritative source appropriate to the question; labeling is especially important for approved indications, dosing,
contraindications, warnings and administration.
• DailyMed provides current labeling information for marketed drugs; product-specific labeling should be checked for exact
formulation details.
• Specialized references can be valuable for interactions, injectable compatibility, toxicology and natural products.
• Never rely on a remembered dose when patient-specific factors could alter dosing.
Regulatory concepts
FDA approval reflects review of evidence that a drug's benefits outweigh known and potential risks for its intended population. The
modern development pathway moves from discovery/preclinical work through human clinical research, FDA review and post-market
safety monitoring. ■cite■turn1search2■turn1search6■
The public preview's controlled-substance questions reflect older U.S. scheduling content. DEA currently describes Schedule II
drugs as having high abuse potential with potential for severe dependence, while Schedules III–V represent progressively lower
Pharmacotherapy Principles & Practice 4th Ed — Original Enhanced Study Guide Page 2
, abuse/dependence potential. Meperidine remains an example of a Schedule II drug. ■cite■turn1search7■
3. PHARMACOKINETICS & PHARMACODYNAMICS
Concept Exam-ready definition
Absorption Movement of drug into systemic circulation.
Bioavailability Fraction of administered dose reaching systemic circulation unchanged.
Distribution Reversible movement of drug between blood and tissues.
Metabolism Chemical alteration of drug, often hepatic but not exclusively.
Elimination Removal of drug/metabolites, commonly through renal or hepatic routes.
Half-life Time required for concentration to fall by approximately 50% during the relevant elimination phase.
Pharmacodynamics What the drug does to the body: receptor effects, physiologic responses and clinical outcomes.
Therapeutic index Relationship between toxic and effective exposure; narrower safety margins demand closer monitoring.
Steady state
With repeated dosing, steady state is approached over several elimination half-lives. A longer half-life generally means a longer time
to reach steady state and wash out after discontinuation. Loading doses can be used when rapid attainment of therapeutic
concentration is important and clinically appropriate.
Renal dosing
• Renal impairment can reduce clearance of renally eliminated drugs and metabolites.
• Assess kidney function using the method appropriate to the drug and clinical context; do not assume every eGFR/CrCl estimate is
interchangeable.
• Monitor for accumulation and toxicity and adjust dose and/or interval according to drug-specific guidance.
• Acute kidney injury can change dosing rapidly; a stable chronic estimate may not describe rapidly changing clearance.
Hepatic considerations
• Some drugs depend heavily on hepatic metabolism or biliary elimination.
• Consider liver disease severity, synthetic function, hepatic blood flow and drug-specific metabolism.
• Do not assume an isolated AST/ALT elevation automatically determines a dose adjustment.
4. MEDICATION SAFETY & PATIENT-CARE PROCESS
• Verify indication, allergy history, medication list, interactions, contraindications and patient-specific risks.
• Use medication reconciliation at transitions of care.
• Confirm the exact product, concentration, route, dose and timing.
• High-alert medications deserve additional safeguards and monitoring.
• Teach what the medication is for, how to take it, expected benefits, common adverse effects, serious warning signs and what to do
if a dose is missed.
• Document response and adverse effects rather than assuming adherence from a prescription record.
Medication reconciliation
The public preview emphasizes using reliable medication-history sources when a patient cannot identify medications. In practice,
reconcile the patient's report with pharmacy records, medication containers, electronic records, caregivers and other reliable sources
when appropriate. ■cite■turn0view0■
5. GERIATRIC PHARMACOTHERAPY
Pharmacotherapy Principles & Practice 4th Ed — Original Enhanced Study Guide Page 3
4th Edition — Chisholm-Burns and colleagues
Enhanced Original Exam Study Guide
Disease-state pharmacotherapy • drug selection • dosing • monitoring • safety • patient care
Created from the public Stuvia preview and the publicly available 4th-edition chapter architecture. This guide is original and does not
reproduce the 344-page paid test bank.
Exam focus: pharmacology foundations • medication safety • geriatrics • pediatrics • palliative care • cardiovascular • respiratory • GI
• renal/electrolytes • neurologic • psychiatric • infectious disease • endocrine • hematology • oncology • rheumatology • dermatology •
women's/men's health • patient monitoring
Pharmacotherapy Principles & Practice 4th Ed — Original Enhanced Study Guide Page 1
, 1. SOURCE REVIEW & STUDY STRATEGY
The linked Stuvia listing is a 344-page Q&A;/test-bank document written for academic year 2021/2022, uploaded January 7, 2022
and updated January 13, 2022. Its public preview starts with Chapter 1 and questions on generic/official drug names,
drug-information resources, FDA approval, controlled-substance scheduling, OTC drugs, injectable references, and
medication-history reconciliation. ■cite■turn0view0■
The official McGraw Hill listing identifies the 4th edition as a 2015 publication (copyright 2016) by Marie A. Chisholm-Burns, Terry L.
Schwinghammer, Barbara G. Wells, Patrick M. Malone, Joseph T. DiPiro and Jill M. Kolesar. The text uses disease-based chapters
with clinical presentation/diagnosis, patient encounters, therapeutic recommendations, dosing and monitoring.
■cite■turn0search0■turn0search7■
Publicly available contents show four introductory chapters followed by 98 disease-based chapters. The organ-system sections
include cardiovascular, respiratory, gastrointestinal, renal, neurologic, psychiatric, infectious disease, endocrine,
hematologic/oncologic, rheumatologic, dermatologic and other common clinical areas. ■cite■turn0search1■turn0search5■
How to study a pharmacotherapy chapter
• 1) Identify the disease and therapeutic goals.
• 2) Confirm diagnosis and severity.
• 3) Identify patient-specific factors: age, pregnancy, renal/hepatic function, allergies, comorbidities and prior treatment.
• 4) Choose nonpharmacologic and pharmacologic therapy.
• 5) Select the agent using efficacy, safety, contraindications, interactions, adherence and cost/access.
• 6) Define starting dose, titration and duration.
• 7) Establish monitoring and measurable treatment targets.
• 8) Reassess response and adverse effects; de-escalate or intensify when indicated.
2. FOUNDATIONS OF PHARMACOTHERAPY
Drug names
Name Meaning
Chemical Describes molecular structure; usually least useful for routine patient communication.
Generic/nonproprietary Standardized name used across manufacturers.
Brand/proprietary Manufacturer-associated trade name.
Official Name recognized in an official compendium/regulatory context; terminology can differ from generic usage.
Drug information hierarchy
• Use the most authoritative source appropriate to the question; labeling is especially important for approved indications, dosing,
contraindications, warnings and administration.
• DailyMed provides current labeling information for marketed drugs; product-specific labeling should be checked for exact
formulation details.
• Specialized references can be valuable for interactions, injectable compatibility, toxicology and natural products.
• Never rely on a remembered dose when patient-specific factors could alter dosing.
Regulatory concepts
FDA approval reflects review of evidence that a drug's benefits outweigh known and potential risks for its intended population. The
modern development pathway moves from discovery/preclinical work through human clinical research, FDA review and post-market
safety monitoring. ■cite■turn1search2■turn1search6■
The public preview's controlled-substance questions reflect older U.S. scheduling content. DEA currently describes Schedule II
drugs as having high abuse potential with potential for severe dependence, while Schedules III–V represent progressively lower
Pharmacotherapy Principles & Practice 4th Ed — Original Enhanced Study Guide Page 2
, abuse/dependence potential. Meperidine remains an example of a Schedule II drug. ■cite■turn1search7■
3. PHARMACOKINETICS & PHARMACODYNAMICS
Concept Exam-ready definition
Absorption Movement of drug into systemic circulation.
Bioavailability Fraction of administered dose reaching systemic circulation unchanged.
Distribution Reversible movement of drug between blood and tissues.
Metabolism Chemical alteration of drug, often hepatic but not exclusively.
Elimination Removal of drug/metabolites, commonly through renal or hepatic routes.
Half-life Time required for concentration to fall by approximately 50% during the relevant elimination phase.
Pharmacodynamics What the drug does to the body: receptor effects, physiologic responses and clinical outcomes.
Therapeutic index Relationship between toxic and effective exposure; narrower safety margins demand closer monitoring.
Steady state
With repeated dosing, steady state is approached over several elimination half-lives. A longer half-life generally means a longer time
to reach steady state and wash out after discontinuation. Loading doses can be used when rapid attainment of therapeutic
concentration is important and clinically appropriate.
Renal dosing
• Renal impairment can reduce clearance of renally eliminated drugs and metabolites.
• Assess kidney function using the method appropriate to the drug and clinical context; do not assume every eGFR/CrCl estimate is
interchangeable.
• Monitor for accumulation and toxicity and adjust dose and/or interval according to drug-specific guidance.
• Acute kidney injury can change dosing rapidly; a stable chronic estimate may not describe rapidly changing clearance.
Hepatic considerations
• Some drugs depend heavily on hepatic metabolism or biliary elimination.
• Consider liver disease severity, synthetic function, hepatic blood flow and drug-specific metabolism.
• Do not assume an isolated AST/ALT elevation automatically determines a dose adjustment.
4. MEDICATION SAFETY & PATIENT-CARE PROCESS
• Verify indication, allergy history, medication list, interactions, contraindications and patient-specific risks.
• Use medication reconciliation at transitions of care.
• Confirm the exact product, concentration, route, dose and timing.
• High-alert medications deserve additional safeguards and monitoring.
• Teach what the medication is for, how to take it, expected benefits, common adverse effects, serious warning signs and what to do
if a dose is missed.
• Document response and adverse effects rather than assuming adherence from a prescription record.
Medication reconciliation
The public preview emphasizes using reliable medication-history sources when a patient cannot identify medications. In practice,
reconcile the patient's report with pharmacy records, medication containers, electronic records, caregivers and other reliable sources
when appropriate. ■cite■turn0view0■
5. GERIATRIC PHARMACOTHERAPY
Pharmacotherapy Principles & Practice 4th Ed — Original Enhanced Study Guide Page 3
